What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall involving a specific pharmaceutical ingredient manufactured by Shoolin Pharma Chem LLP. The product at the center of this notice is TADALAFIL USP, supplied in 0.500 KG (500-gram) bags. This is not a finished consumer medication you would find on a pharmacy shelf ready for immediate use; rather, it is a raw active pharmaceutical ingredient intended strictly "For Prescription Compounding Only." The designation "Rx only" further confirms that this material is regulated for professional use by licensed pharmacists or healthcare providers who compound medications from bulk ingredients, rather than for direct patient administration in its current form.
The specific batch affected by this recall is identified as Batch TLF2506001. Each unit within this batch carries the National Drug Code (NDC) 85702-002-04 and is associated with the chemical identifier CAS NO 171596-29-5. The product is manufactured by Shoolin Pharma Chem LLP, located at Block/Survey no 408, B/H Ratnamani Tubes, Near Maruti Inox, Indrad, Kadi, Mahesania, Gujarat, 382715, India. While the manufacturing origin is international, the scope of this recall is domestic, as these bags were distributed nationwide across the United States. The product carries an expiration date of May 31, 2028, indicating that the material was chemically stable at the time of distribution but has now been flagged for regulatory intervention.
The recall was officially initiated on August 3, 2026. It is classified as a Class II recall by the FDA, which indicates a situation where use of or exposure to the product may cause temporary or medically reversible serious adverse health consequences, or where the probability of serious adverse health consequences is remote. In this instance, the primary driver for the recall is not necessarily a confirmed chemical contamination or immediate safety failure in the field, but rather Good Manufacturing Practice (CGMP) deviations. These deviations were noted during an FDA inspection of the manufacturing facility. CGMP standards are rigorous protocols designed to ensure that products are consistently produced and controlled according to quality standards. When these standards are not met, it raises concerns about the purity, strength, quality, or consistency of the drug substance, which is why the FDA requires its removal from the supply chain regardless of whether specific illnesses have been reported.
If you are a compounding pharmacist, healthcare provider, or distributor who may have received this product, it is critical to verify your inventory against these exact details. The recall applies specifically to the 500-gram bags of TADALAFIL USP under the brand Shoolin Pharma Chem LLP. Because the distribution pattern was nationwide, the affected units could be in any state, making thorough record-checking essential for anyone who handles bulk pharmaceutical ingredients.
The hazard, explained
At first glance, the recall notice from the FDA regarding Shoolin Pharma Chem LLP’s Tadalafil USP might seem technical and dry, but the underlying issue is fundamentally about trust in manufacturing standards. The official classification for this recall is "Class II," which indicates a situation where exposure to the product could cause temporary or medically reversible health problems, though the risk of serious injury is not impossible. The primary reason for this classification lies in what regulators call "CGMP Deviations." CGMP stands for Current Good Manufacturing Practices, a rigorous set of federal guidelines designed to ensure that every batch of medicine is produced with consistent quality, strength, purity, and identity. When these deviations are noted during an FDA inspection, it does not necessarily mean the drug is poisonous or ineffective right now. Instead, it means there was no guarantee that the product met those strict standards.
To understand why this matters, we have to look at what goes wrong behind the scenes in a non-compliant facility. Good Manufacturing Practices require meticulous control over everything from the cleanliness of the air and equipment to the precise weighing of ingredients and the temperature of storage. If these controls fail, several physical risks can emerge. For a substance like Tadalafil, which is a potent active pharmaceutical ingredient used to treat erectile dysfunction and pulmonary arterial hypertension, consistency is critical. A deviation might mean that the chemical composition of the 500-gram bags was not uniform. One bag might have slightly too much of the active drug, while another has too little. In the world of compounding pharmacy, where pharmacists mix this raw material into final prescriptions for individual patients, even small variations can lead to significant dosage errors.
If the Tadalafil contains impurities due to poor manufacturing controls, those contaminants could trigger unexpected allergic reactions or interact dangerously with other medications a patient is taking. Furthermore, if the degradation of the chemical structure was not properly monitored, the drug might lose its potency entirely. This leaves patients without the therapeutic benefit they were prescribed, which can be particularly dangerous for those using it to manage pulmonary arterial hypertension, where consistent blood pressure regulation is vital for heart health. While the recall facts do not list specific incidents of injury or illness at this time, the potential for harm exists in the uncertainty. You cannot know if your specific bottle from Batch TLF2506001 was made under perfect conditions or if a step in the process was skipped. This lack of transparency is what creates the hazard: you are taking a medication whose safety and efficacy profile is unknown.
It is also important to note that this product was labeled "For Prescription Compounding Only." This means it was never intended to be sold directly to consumers as a finished pill. Instead, it was shipped to compounding pharmacies across the nation to be processed further. The hazard, therefore, extends beyond just the raw powder. It affects every patient who received a compounded prescription from a pharmacy that sourced this specific batch. Because the distribution pattern was nationwide, the reach of this potential issue is broad. The physical failure here is not an explosion or a leak, but a silent failure of quality control that undermines the very foundation of pharmaceutical safety: knowing exactly what you are putting into your body.
Who is most at risk
To understand who faces the greatest potential impact from this recall, we first need to look closely at what the product actually is and how it moves through the healthcare system. The item in question is Tadalafil USP, a pharmaceutical ingredient distributed by Shoolin Pharma Chem LLP. Crucially, the packaging explicitly states "For Prescription Compounding Only." This designation changes the entire risk landscape compared to a recall of a finished, ready-to-take medication like a branded pill bottle found in your medicine cabinet. Because this product is a raw active pharmaceutical ingredient (API) packaged in 0.500 KG bags, it is not intended for direct patient consumption. Therefore, the general public, including families with children or elderly relatives managing their own prescriptions at home, are not directly at risk of ingesting this specific recalled material.
The primary group at potential risk consists of healthcare professionals and compounding pharmacies that have received this specific batch. These are the entities responsible for taking the raw powder and mixing it into customized medications for patients. The recall classification is Class II, which indicates a situation where use or exposure to the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. However, even with a Class II classification, the stakes are high for the compounding pharmacists who handle Batch TLF2506001, which expires on May 31, 2028. If these professionals fail to identify and quarantine the product due to Good Manufacturing Practice (CGMP) deviations noted during FDA inspection, they may inadvertently create compounded drugs that do not meet the strict quality standards required for safety and efficacy.
The secondary group at risk are the patients who receive prescriptions from those compounding pharmacies. While the hazard stems from manufacturing deviations rather than a known toxic contamination, the integrity of the drug depends entirely on the purity and consistency of its ingredients. Tadalafil is commonly used to treat erectile dysfunction and pulmonary arterial hypertension. For patients with cardiovascular conditions, relying on medication that may have inconsistent potency or impurities due to CGMP failures could lead to subtherapeutic effects—meaning the drug might not work as intended—or unexpected side effects. Although the FDA has not reported specific incidents of injury related to this recall yet, the vulnerability lies in the gap between manufacturing standards and patient safety. Any individual relying on a compounded version of Tadalafil from a pharmacy that may have sourced this specific Shoolin Pharma Chem batch is theoretically exposed to this risk until they verify the drug's source. It is important to note that without a reported remedy or list of affected distributors, patients cannot easily determine if their current prescription was filled with this material, making proactive communication with their pharmacist essential.
How to tell if you have the recalled item
Identifying whether your medication or pharmaceutical ingredients are part of this specific FDA recall requires a careful, methodical approach. Because this recall involves a bulk raw material rather than a finished consumer product sold directly in pharmacies, the identification process focuses on precise manufacturing details and packaging specifications. If you are a healthcare provider, pharmacy technician, or compounding specialist who may have received this shipment, do not rely on general assumptions about the drug name alone. You must verify the specific batch and manufacturer data against the official recall notice.
The primary item under recall is Tadalafil USP, supplied in 0.500 KG (500 grams) bags. This is a critical distinction; this is not the small tablet blister packs you might be familiar with for personal use. It is a bulk ingredient intended "For Prescription Compounding Only." Therefore, if you are an individual patient looking at your home medicine cabinet, it is highly unlikely you possess this specific recalled item, as it is distributed to professionals for further processing. However, if you are in the supply chain or a compounding pharmacy, you must inspect your inventory immediately.
To confirm if you have the affected product, look for the following exact identifiers on the packaging and documentation:
- Manufacturer Name: The product must be manufactured by Shoolin Pharma Chem LLP. Check the label or certificate of analysis to ensure this is the correct entity.
- Product Description: Verify the item is labeled as "TADALAFIL USP." It should explicitly state the quantity as "0.500 KG" or "0.500KG(500gm)-bag."
- NDC Number: Look for the National Drug Code 85702-002-04. This unique identifier is your most reliable way to cross-reference your stock against the FDA database.
- Batch/Lot Number: The specific batch involved is TLF2506001. If your inventory shows a different lot number, it may not be part of this specific recall action, but you should still verify with the supplier.
- Expiry Date: The recalled batch has an expiration date of May 31, 2028. While the expiry date alone does not confirm a recall, it helps narrow down the timeframe of manufacture and distribution.
- CAS Number: The chemical abstract service number listed is 171596-29-5. This confirms the chemical identity but should be used in conjunction with the other identifiers above.
Additionally, consider the origin and distribution pattern. This product was manufactured in India, specifically at Block/Survey no 408, B/H Ratnamani Tubes, Near Maruti Inox, Indrad, Kadi, Mahesania, Gujarat, 382715. While you may not see this full address on the immediate bag label, it will be present in your shipping documents and bills of lading. The product was distributed nationwide across the USA. If you received a shipment of Tadalafil USP from Shoolin Pharma Chem LLP around the recall date of August 3, 2026, or if your records indicate this specific NDC and batch number, you must treat it as potentially affected.
If you are unsure, do not attempt to use the product for compounding. The recall is classified as a Class II recall, indicating that use of the product might cause temporary or medically reversible health problems, or the probability of serious adverse effects is remote, but the CGMP (Current Good Manufacturing Practice) deviations noted during FDA inspection mean the quality and purity cannot be guaranteed without further testing. When in doubt, contact your supplier directly for verification before proceeding.
What to do — step by step
Because the official recall notice for this specific batch of Tadalafil USP distributed by Shoolin Pharma Chem LLP does not state a specific remedy—such as a return address, a direct refund process, or an authorized repair center—you must take proactive steps to ensure your safety. When the government issues a Class II recall due to Current Good Manufacturing Practice (CGMP) deviations, it indicates that the product may be unsafe for its intended use or could cause temporary health problems. Since the regulatory body has identified potential contamination or quality control failures during their inspection, you cannot assume the medication is safe to consume even if it looks and smells normal. Your immediate priority is to remove this product from your pharmacy or compounding workflow entirely.
- Stop Use Immediately: If you are a healthcare provider, pharmacist, or compounding technician who has received this material, cease all handling and use of the Tadalafil USP (NDC 85702-002-04) right away. Do not compound any prescriptions using this specific ingredient. The deviation noted during the FDA inspection suggests that the purity or potency may not meet standard specifications, which could lead to incorrect dosing or adverse reactions in patients.
- Secure and Isolate the Product: Physically separate the recalled bags (specifically those with Batch Number TLF2506001, expiring May 31, 2028) from your inventory. Place them in a clearly marked, restricted area to prevent accidental dispensing or use by other staff members. This is critical because the product was distributed nationwide, meaning it may be mixed with non-recalled stock in some facilities.
- Contact the Distributor for Disposition Instructions: Since the recall notice does not provide a government-managed return portal or a specific remedy, you must contact Shoolin Pharma Chem LLP directly to ask how they want you to dispose of the product. They may require you to ship the items back for destruction or provide local disposal guidelines. Do not throw the medication in the household trash or flush it down the toilet unless explicitly instructed to do so by the manufacturer, as this can harm the environment.
- Notify Affected Patients: If you have already dispensed compounded prescriptions using this batch, you must contact your patients immediately. Explain that a quality control issue has been identified and advise them on what steps to take next, such as consulting their physician for an alternative source of medication. Transparency here is vital for maintaining trust and ensuring patient safety.
- Document Everything: Keep records of your communication with Shoolin Pharma Chem LLP, including any emails, letters, or phone logs regarding the return or disposal of the product. You may need this documentation to prove that you acted promptly in compliance with federal regulations.
Remember, when the remedy is not explicitly stated in the initial recall announcement, the burden shifts to you to establish contact with the responsible party to determine the correct course of action. Until you receive specific instructions from Shoolin Pharma Chem LLP regarding returns or refunds, treat the product as hazardous waste that must be kept out of circulation.
Your refund, repair, or replacement options
When a pharmaceutical product is recalled, the most immediate question for consumers and healthcare providers alike is often, "What happens to the product I already have, and how do I make things right?" In this specific instance involving Shoolin Pharma Chem LLP’s recall of Tadalafil USP, it is important to approach the situation with clarity and calm. The official FDA recall notice, dated August 3, 2026, provides specific details about the hazard—CGMP (Current Good Manufacturing Practice) deviations—but notably does not explicitly state a standard consumer remedy such as a direct refund, repair, or replacement in the public summary provided. This absence of a stated monetary or exchange remedy is common in Class II drug recalls that involve manufacturing quality issues rather than immediate toxic hazards, but it requires a different set of actions on your part. Because the recall classification is Class II, this indicates that use of the product could cause temporary health problems or pose a slight severity of threat, but is not likely to cause serious adverse health consequences. However, the deviation from CGMP standards means the integrity of the drug cannot be guaranteed. Therefore, your primary "option" is not necessarily seeking a financial refund directly from the manufacturer in the way you might return a defective appliance, but rather ensuring the product is safely removed from your inventory and replaced with a verified, compliant source. The remedy here is effectively the cessation of use and proper disposal or return through professional channels, rather than a consumer-facing repair shop. If you are a healthcare provider or a compounding pharmacy that received this batch (Tadalafil USP, 0.500 KG bag, NDC 85702-002-04, Batch TLF2506001), your path forward involves contacting the distributor or the supplier from whom you purchased the goods. The recall notice identifies Shoolin Pharma Chem LLP as the responsible party, located in Gujarat, India. You should reach out to them directly to inquire about their specific return logistics for CGMP deviations. They may offer a credit against future orders or arrange for the return shipping of the affected 500-gram bags. It is crucial to document all communications with the supplier, as this documentation may be necessary for your own quality assurance records and regulatory compliance. For individual patients who have been prescribed medication compounded from this specific batch, you do not need to seek a refund from Shoolin Pharma Chem LLP directly. Instead, your remedy lies with your prescribing physician or the pharmacy that filled your prescription. You should contact them immediately to inform them of the recall. They will typically replace the dispensed medication with a new prescription filled using Tadalafil from a different, compliant manufacturer or batch. In many cases, pharmacies will absorb the cost of the dispensed recalled product as part of their professional liability and customer care protocols, meaning you may not face an out-of-pocket charge for the replacement. However, this is at the discretion of your pharmacy, so it is best to ask them directly about their specific policy on recalled compounded drugs. In summary, while a direct "refund" option is not explicitly listed in the FDA notice, the practical remedy involves: 1) Healthcare providers contacting Shoolin Pharma Chem LLP for return instructions and potential credits; and 2) Patients working with their pharmacies to obtain a new, safe supply of medication without financial penalty. Always prioritize your health by stopping use of any Tadalafil from Batch TLF2506001 immediately and consulting your healthcare provider for guidance on alternative treatments.What can happen if you ignore it
When a pharmaceutical recall is issued due to Current Good Manufacturing Practice (CGMP) deviations, the immediate concern is not necessarily that the medication is "poisoned" in the traditional sense, but rather that its reliability and safety profile cannot be guaranteed. In this specific case involving Shoolin Pharma Chem LLP’s Tadalafil USP, the FDA identified manufacturing irregularities during an inspection. While the recall notice does not list specific reported injuries or adverse events at this time, ignoring a Class II recall carries significant, albeit often subtle, risks that extend far beyond a simple inconvenience. The primary danger of continuing to use tadalafil from this recalled batch lies in the unpredictability of its potency. CGMP deviations can lead to variations in how the active ingredient is mixed or processed. This means the pill might contain too little of the drug, rendering it ineffective for treating erectile dysfunction or pulmonary arterial hypertension. For individuals relying on this medication for consistent management of their condition, an under-dosed product can lead to a false sense of security followed by unexpected treatment failure. Conversely, if the deviation resulted in over-potency or contamination during the compounding process, the risk shifts to potential overdose symptoms. Tadalafil affects blood pressure and heart rate; taking a dose that is stronger than labeled can cause dangerous drops in blood pressure, severe headaches, dizziness, or prolonged erections (priapism) that require emergency medical attention to prevent permanent tissue damage. Furthermore, because this product was marked "For Prescription Compounding Only," it was intended for pharmacists to mix into final doses. If a consumer has obtained this raw material directly or through an unverified channel and is attempting to use it without professional oversight, the risks are compounded. Improper handling of bulk pharmaceutical ingredients can lead to chemical degradation or contamination with other substances not present in the original formulation. Ignoring the recall means you are effectively conducting your own unmonitored experiment with a substance whose quality control history is now in question. There is also the risk of drug interactions becoming unpredictable. If the purity of the tadalafil is compromised due to manufacturing errors, it may interact differently with other medications you are taking, such as nitrates or alpha-blockers. This could lead to unexpected cardiovascular events. While no specific incidents have been reported in this recall announcement, the nature of CGMP violations suggests that the consistency required for safe long-term use is absent. By ignoring the recall, you are accepting a gamble with your health, relying on luck rather than the rigorous safety standards that are supposed to protect patients. The uncertainty itself is a significant health risk, as it prevents doctors from accurately diagnosing or treating underlying conditions if the medication fails to work as expected.Staying safe: broader tips
When it comes to pharmaceutical products, especially those intended for prescription compounding, safety relies heavily on vigilance and proper supply chain management. While this specific recall highlights deviations from Current Good Manufacturing Practices (CGMP), the broader lesson applies to all consumers who rely on medication for their health. One of the most effective ways to stay safe is to maintain an open line of communication with your healthcare provider and pharmacist. They are your first line of defense against quality issues. If you ever notice that a medication looks different than usual—whether in color, texture, or packaging—do not hesitate to question it. Good manufacturing practices ensure consistency, so any deviation from the norm is worth investigating immediately.
It is also crucial to understand where your medications come from. For compounded drugs, which are often custom-made for individual patients, the reputation and regulatory standing of the compounding pharmacy are paramount. Regularly check if your pharmacy or supplier has received any warnings from the FDA or other regulatory bodies. You can do this by visiting the FDA’s official website, which maintains a comprehensive database of all drug recalls. Subscribing to email alerts from the FDA can ensure you are notified quickly if a product you use is affected by a new safety issue. This proactive approach allows you to act before any potential harm occurs.
Additionally, proper storage and handling of medications at home play a significant role in maintaining their integrity. Even if a drug passes initial quality checks, improper storage can degrade its efficacy or create safety hazards. Always follow the storage instructions provided on the label, such as keeping medications in a cool, dry place away from direct sunlight. For compounded preparations, which may lack the preservatives found in mass-produced drugs, adhering to expiration dates and storage conditions is even more critical.
Finally, stay informed about general health and safety trends. Regularly reviewing recall notices for other categories of products you use at home can help you develop a habit of scrutiny. Whether it’s checking for recalled baby products, home appliances, or food items, this mindset of active awareness can protect your family from a wide range of potential hazards. By staying educated and engaged with official safety resources, you empower yourself to make informed decisions about your health and well-being.